Latest Posts


Mar 24

Partex NV announces collaboration with Althea DRF Lifesciences to provide comprehensive end-to-end services to accelerate drug discovery and development

Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF...
Read More


Mar 24

Innovative AI technology in oncology: Partex Group presents results from a pilot project

During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More

FDA supports AI for drug development

AI technologies are more widely used in the pharmaceutical industry today to enable for its extensive review of scientific and medical literature. Extensive data obtained through AI can support the discovery of potential biomarkers, accelerate drug development and identify repurposing opportunities.1 The FDA sees tremendous potential in technologies such as machine and deep learning in healthcare.

Keen interest in using automated technologies is rapidly expanding across the pharmaceutical and biotechnology industries. The FDA, has been developing a new regulatory framework to promote innovation and to “support the use of AI-based technologies”, according to Dr. Scott Gottlieb, the FDA Commissioner, speaking in 2018 at the Health Datapalooza in Washington DC. “AI holds enormous promise for the future of medicine,” said Gottlieb.

The industry has established the use of AI models and algorithms in order to speed up the analysis of large datasets to identify potential drug candidates. The process is much faster than manual analysis where a researcher is generally able to annotate upto 300 articles in a year. When compared, the efficiency of machine learning tools is not only unquestionable, but also the insights generated through search queries are accurate, relevant and based on the latest published research.

Using AI technologies and AI-based tools, scientific literature can be utilized to generate disease insights and develop more robust hypotheses. Owing to these advantages, the world’s first AI-generated drug, DSP-1181, a compound expected to treat obsessive-compulsive disorder has already entered Phase I of clinical trials earlier in 2020.2 The key milestone in healthcare was achieved by Sumitomo Dainippon Pharma. By using AI technologies, drug discovery time was reduced from 4-5 years to 1 year.

In 2017, the FDA issued a ‘Digital Health Innovation Action Plan’3 to outline its approach to implement effective technologies in healthcare and support the use of AI-based applications in research and drug development. Moreover, the FDA is supporting initiatives to develop and apply advanced predictive models in streamlining the drug review process.4 With an efficient regulatory framework, safe and effective therapies can be discovered, developed, and marketed much faster than ever.


Featured Blogs